## **Special Issue**

# Advances in Proton Pencil Beam Scanning Therapy

## Message from the Guest Editors

Proton pencil beam scanning (PBS) is a technology in which a narrow beam of charged particles is used to treat complex cancers with unparalleled precision. The beam is energized and deflected such that it mirrors the tumor's shape for maximum conformality. This reduces the risk of side effects that are associated with standard radiation therapy. This Special Issue will focus on the latest developments in PBS. Manuscripts reflecting original research, as well as critical review articles on current knowledge and future perspectives, will be welcome. The Special Issue will address topics such as improvements in beam delivery systems, selecting optimal PBS parameters for cancer treatment, clinical outcomes based on the dosimetric and biological modeling of proton therapy, and reductions in secondary cancer risks, among others. The Special Issue shall also report on the limitations and future directions of proton PBS. This Special Issue will be an excellent resource for researchers and clinicians who are interested in learning about recent advancements in proton pencil beam scanning therapy for cancer treatment.

#### **Guest Editors**

Dr. Nicolas Depauw

Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

Dr. Sara St. James

Huntsman Cancer Institute, 2000 Circle of Hope Dr, Salt Lake City, UT 84112, USA

## Deadline for manuscript submissions

closed (1 September 2024)



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/189092

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com\_

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

